Skip to main content
Journal cover image

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Publication ,  Journal Article
Wahezi, DM; Ilowite, NT; Wu, XX; Pelkmans, L; Laat, B; Schanberg, LE; Rand, JH ...
Published in: Lupus
June 2013

Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24% versus 177 ± 30% (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lupus

DOI

EISSN

1477-0962

Publication Date

June 2013

Volume

22

Issue

7

Start / End Page

702 / 711

Location

England

Related Subject Headings

  • beta 2-Glycoprotein I
  • Young Adult
  • Prospective Studies
  • Multivariate Analysis
  • Male
  • Lupus Erythematosus, Systemic
  • Lupus Coagulation Inhibitor
  • Immunoglobulin G
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wahezi, D. M., Ilowite, N. T., Wu, X. X., Pelkmans, L., Laat, B., Schanberg, L. E., … Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators, . (2013). Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus, 22(7), 702–711. https://doi.org/10.1177/0961203313490241
Wahezi, D. M., N. T. Ilowite, X. X. Wu, L. Pelkmans, B. Laat, L. E. Schanberg, J. H. Rand, and J. H. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. “Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.Lupus 22, no. 7 (June 2013): 702–11. https://doi.org/10.1177/0961203313490241.
Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013 Jun;22(7):702–11.
Wahezi, D. M., et al. “Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.Lupus, vol. 22, no. 7, June 2013, pp. 702–11. Pubmed, doi:10.1177/0961203313490241.
Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, Rand JH, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013 Jun;22(7):702–711.
Journal cover image

Published In

Lupus

DOI

EISSN

1477-0962

Publication Date

June 2013

Volume

22

Issue

7

Start / End Page

702 / 711

Location

England

Related Subject Headings

  • beta 2-Glycoprotein I
  • Young Adult
  • Prospective Studies
  • Multivariate Analysis
  • Male
  • Lupus Erythematosus, Systemic
  • Lupus Coagulation Inhibitor
  • Immunoglobulin G
  • Humans
  • Follow-Up Studies